Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

However, after its phase 1 success with TERN-601, it will raise more money by taking advantage of its soaring stock price and ...

A new weight loss pill called amycretin has helped people lose up to 13% of their body weight in just three months, according ...

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...